ALS EXPERTS' PERSPECTIVESRADICAVA ORS® can fit their life's routines with a 5 mL oral dose of a proven treatment.2
DISCOVER RADICAVA ORS®
FDA recognizes RADICAVA ORS® as MAJOR CONTRIBUTION TO PATIENT CARE1. To learn more, Download brochure.
the difference is experience
RADICAVA ORS® (edaravone) offers the same efficacy as RADICAVA® (edaravone) in an oral formulation.2,3
RADICAVA ORS® is recognized by the FDA as a
Major Contribution to Patient Care1
16,000+ people have been treated
with RADICAVA® for 1.9 million+ days
of therapy4,a,b (see footnote)
RADICAVA® has been prescribed by
2400+ physicians4,a (see footnote)
Proven Efficacy in an
Oral Formulation
33% less change in ALSFRS-R scores from baseline vs placebo at 24 weeks.1,3
Flexible Administration with Oral Dosing
5mL dose administered in minutes orally or through PEG/NG tube with oral syringe.1
Starting Patients & Cost Support Options
Review steps to beginning or transitioning to oral treatment that can fit into their daily routine.1
RADICAVA® helps slow the loss of physical function in patients with ALS2,10For Your Moments Big and Small
The JourneyMate Support Program™ helps to give patients understanding, answers, and resources to supplement what their doctor provides. Experienced program team members are trained to address patient educational needs and provide them with personalized answers and resources for living with ALS.
ALS=Amyotrophic lateral sclerosis; HCP=Healthcare provider; NG=nasogastric; PEG=percutaneous endoscopy gastrostomy.
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of May 2024. Not independently verified. Return to content
bDays of therapy based on number of RADICAVA ORS® and RADICAVA® IV cartons sold as of May 2024. Each carton represents a day’s supply of therapy. Return to content
References: 1. US Food and Drug Administration. Clinical superiority findings. Accessed April 11, 2024. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinicalsuperiority-findings 2. RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022. 3. Shimizu H, Nishimura Y, Shiide Y, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188-1197. 4. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc. 5. Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler. 2006;7(4):241-245. 6. ClinicalTrials.gov. Safety study of oral edaravone administered in subjects with ALS. Accessed April 11, 2024. https://clinicaltrials.gov/study/NCT04165824 7. Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLoS One. 2022;17(6):e0258614. 8. Takei K, Watanabe K, Yuki S, et al. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):5-10. 9. US Food and Drug Administration. FDA approves oral form for the treatment of adults with amyotrophic lateral sclerosis (ALS). Accessed April 11, 2024. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-oral-form-treatment-adults-amyotrophic-lateral-sclerosis-als 10. Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512.
